CFC-powered inhalers inclusion in FDA reform bill agreed to by Sen. Kennedy.
This article was originally published in The Gray Sheet
Executive SummarySEN. KENNEDY TO SUPPORT INCLUSION OF CFC-POWERED INHALERS BILLS IN S 830 during conference of the FDA reform bill. The Massachusetts Democrat is understood to be willing to accept the inclusion of Sen. Tim Hutchinson's (R-Ark.) S 1299, and its companion legislation in the House, Rep. Mark Foley's (R-Fla.) HR 2627, which would prevent FDA from banning metered-dose inhalers for asthma which use chlorofluorocarbons as the propellant until acceptable alternative products are available.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.